Every morning in hospitals around the world, clinicians review panels of numbers before touching a single patient. Serum creatinine tells them whether kidneys are filtering adequately. Troponin tells them whether heart muscle has been injured overnight. Glucose and hemoglobin A1c tell them where a patient stands on the spectrum between metabolic health and diabetes. Bilirubin and transaminases map the function and injury state of the liver. These numbers are not incidental data points. They are the biochemical narrative of what is happening inside the human body, and they are produced by clinical chemistry, the laboratory discipline dedicated to measuring chemical constituents in blood, urine, and other body fluids for the purpose of diagnosing, monitoring, and managing disease.
The role of clinical chemistry in disease diagnosis is foundational in a way that is easy to underestimate because it is invisible to most patients. Clinical chemistry operates entirely behind the scenes, conducted by medical laboratory scientists using automated analyzers, validated reagents, and quality-controlled methods that produce results within minutes to hours of specimen receipt. Yet the breadth of diagnostic territory it covers is extraordinary. The global clinical chemistry market, which encompasses analyzers, reagents, and consumables used in this field, was valued at approximately $15.11 billion in 2024 and is projected to grow to $22.06 billion by 2029, reflecting both the rising global burden of chronic disease and the expanding catalog of biochemical parameters that clinical laboratories can now measure with clinical precision. The World Health Organization estimates that chronic diseases account for nearly 71 percent of all global deaths, and the majority of the laboratory testing that tracks, diagnoses, and monitors those conditions falls within clinical chemistry.
This article examines what clinical chemistry is, which analytes it measures and why they matter diagnostically, how specific disease areas depend on clinical chemistry testing, and what the evolving biomarker landscape means for the future of diagnosis.
What Clinical Chemistry Measures and Why It Matters
Clinical chemistry encompasses the quantitative measurement of chemical constituents in human specimens. Blood, whether as whole blood, serum, or plasma, is the most common specimen matrix, but urine, cerebrospinal fluid, pleural fluid, and other body fluids are also analyzed. The analytes measured range from simple small molecules such as glucose and electrolytes to complex proteins such as albumin and cardiac troponin, and from hormones and enzymes to lipids, drugs, and tumor-associated antigens.
The diagnostic power of clinical chemistry rests on a fundamental principle: the concentrations of specific chemicals in the body vary predictably between health and disease, which is the basis for using them as biomarkers in disease diagnosis. When a pancreatic beta cell fails to produce insulin, blood glucose rises above the normal fasting range. When myocardial cells die during a heart attack, they release troponin into the circulation. When the liver is damaged by viral hepatitis, the enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST) leak out of injured hepatocytes and appear in blood at concentrations many times above their normal upper limits. Clinical chemistry measures these deviations and, through the interpretive framework of reference intervals and decision limits, translates raw concentrations into actionable clinical information.
The scope of clinical chemistry testing has expanded substantially over the past five decades. Automated analyzers now capable of running more than 200 distinct assays from a single sample have replaced the labor-intensive manual methods that once dominated laboratory practice. The Atellica CI Analyzer by Siemens Healthineers, for example, offers assays across 20 disease states with throughput designed for laboratory networks managing thousands of specimens daily. This automation has increased reproducibility, reduced turnaround time, and made comprehensive metabolic profiling accessible even in moderate-volume laboratories. The resulting volume of clinical chemistry testing performed each year numbers globally in the tens of billions of individual assays, reflecting both routine screening and targeted diagnostic investigations.
Diabetes: The Most Measured Disease in Clinical Chemistry
No disease category illustrates the central role of clinical chemistry in diagnosis more clearly than diabetes mellitus. The International Diabetes Federation projected that the global diabetic population would rise from 537 million in 2021 to 783 million by 2045, and virtually every diagnostic decision in that disease’s trajectory depends on clinical chemistry.
Diabetes is diagnosed using three distinct clinical chemistry measurements, each with precisely defined thresholds recognized by the World Health Organization, the American Diabetes Association, and the American College of Endocrinology. Fasting plasma glucose of 7.0 mmol/L (126 mg/dL) or greater, a two-hour plasma glucose of 11.1 mmol/L (200 mg/dL) or greater during an oral glucose tolerance test, or a hemoglobin A1c (HbA1c) value of 6.5 percent or higher, each measured on two separate occasions in the absence of unequivocal hyperglycemia, constitutes a diagnosis of diabetes.
HbA1c has become the preferred test for both diagnosis and long-term glycemic monitoring because of its practical advantages: it requires no fasting, reflects average plasma glucose over the preceding eight to twelve weeks as glucose becomes irreversibly bound to hemoglobin during the erythrocyte’s lifespan, and can be performed at any time of day. The standardization infrastructure supporting HbA1c testing reflects the investment clinical chemistry has made in ensuring that results are comparable across laboratories worldwide. The National Glycohemoglobin Standardization Program (NGSP) in the United States, and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) reference method procedures globally, ensure that an HbA1c of 6.5 percent means the same thing whether measured in London, Lagos, or Los Angeles.
The utility of HbA1c is not without clinical nuance, however. The WHO recommends its use for diagnosis provided that stringent quality assurance measures are in place and that no conditions are present that would compromise the accuracy of the measurement. Those conditions include hemolytic anemia, thalassemia, sickle cell trait, pregnancy, and renal failure, all of which can produce falsely low or falsely high HbA1c values that do not reflect true glycemic exposure. In such patients, plasma glucose testing remains the required diagnostic method. This clinical reasoning, understanding when a test is reliable and when its limitations require an alternative approach, is part of the interpretive knowledge that clinical chemistry provides to clinicians.
Cardiovascular Disease: Troponin and the Diagnosis of Myocardial Injury
Few clinical chemistry tests carry higher stakes than cardiac troponin in the evaluation of acute chest pain. Troponin I and troponin T are regulatory proteins found in cardiac muscle that are released into the bloodstream when cardiomyocytes are injured or dying. Because they are highly specific to cardiac tissue, their elevation in serum indicates myocardial damage, and their concentration in combination with its change over a short time interval is the cornerstone of diagnosing acute myocardial infarction.
The introduction of high-sensitivity cardiac troponin (hs-cTn) assays has substantially changed how chest pain is evaluated in emergency settings. High-sensitivity assays can detect troponin concentrations in more than 50 percent of apparently healthy individuals, meaning that even small degrees of myocardial stress become detectable. This analytical sensitivity, provided that the assay meets the precision criteria of a coefficient of variation below 10 percent at the 99th percentile reference limit as recommended by the IFCC, enables rapid rule-in and rule-out protocols for acute myocardial infarction that can reduce emergency department evaluation time from hours to under two hours in appropriate patients.
The interpretation of troponin results, however, requires clinical context that illustrates the broader discipline of clinical chemistry interpretation. Chronic kidney disease produces persistently elevated hs-cTn levels even in the absence of acute cardiac events, because reduced renal clearance and structural cardiac remodeling both contribute to circulating troponin concentrations above the 99th percentile used in healthy reference populations. A study from the Salford Kidney Study analyzing data from 1,946 non-dialysis-dependent chronic kidney disease patients found that high-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were strong independent predictors of all-cause mortality, major adverse cardiovascular events, and progression to end-stage kidney disease. During a median follow-up of 71.5 months, 931 patients (47.8 percent) died, 553 (28.4 percent) experienced a major adverse cardiovascular event, and 554 (28.5 percent) reached end-stage kidney disease. These figures underscore that in complex patients, clinical chemistry biomarkers must be interpreted within the full clinical picture, and that rising biomarker trends over serial measurements carry more diagnostic weight than any single value.
BNP and NT-proBNP, the natriuretic peptides released by ventricular wall stress, perform a complementary diagnostic function in heart failure. Elevated BNP or NT-proBNP in a patient presenting with dyspnea provides strong evidence for a cardiac rather than pulmonary origin, guiding immediate management decisions that directly affect survival.
Liver Disease: The Pattern Language of Liver Chemistries
The liver function panel, which typically includes ALT, AST, alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total and direct bilirubin, albumin, and prothrombin time, represents clinical chemistry’s contribution to hepatology. No single analyte in this panel is a complete liver function test, but their patterns in combination allow clinical laboratories to distinguish between hepatocellular injury, cholestatic disease, impaired synthetic function, and conditions that mimic liver disease from elsewhere in the body.
ALT is the most liver-specific enzyme in routine clinical chemistry. It is found in highest concentration in hepatocytes, meaning that elevations above the upper limit of normal are strong indicators of hepatocellular damage. The degree of elevation guides interpretation: moderate elevation, defined as three to ten times the upper reference limit, warrants investigation for viral hepatitis, significant non-alcoholic fatty liver disease, or drug toxicity. Elevations above ten times the upper limit indicate acute liver injury from causes including acute viral hepatitis, ischemic hepatitis, drug-induced liver injury, or autoimmune hepatitis. AST is less liver-specific because it is also present in cardiac and skeletal muscle, but the ratio of AST to ALT carries its own diagnostic language. An AST-to-ALT ratio greater than 2:1, and particularly greater than 3:1, is a classic pattern of alcoholic liver disease, present in approximately 70 percent of such patients, reflecting the selective depletion of pyridoxal phosphate by alcohol which disproportionately reduces ALT synthesis. An ALT-dominant elevation, by contrast, characterizes most other liver pathologies.
ALP elevated out of proportion to transaminases, particularly when accompanied by elevated GGT, indicates a cholestatic pattern, pointing toward bile duct obstruction, primary biliary cholangitis, or primary sclerosing cholangitis. Albumin and prothrombin time assess hepatic synthetic function, and their progressive decline in a patient with liver disease reflects impaired production of proteins that require a functioning liver. The Maddrey discriminant function, which incorporates bilirubin and prothrombin time, was developed specifically to predict severity and guide steroid treatment decisions in alcoholic hepatitis.
The precision and clinical utility of these patterns depend entirely on the accuracy of the measurements underlying them, which is why laboratory quality management, calibration, and external quality assessment matter as much for clinical chemistry as for any other discipline.
Kidney Disease: Chemistry at the Interface of Filtration and Function
The estimated glomerular filtration rate (eGFR), calculated from serum creatinine or cystatin C using population-derived equations, is clinical chemistry’s primary tool for assessing kidney function. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation replaced the older Modification of Diet in Renal Disease (MDRD) formula as the recommended method for eGFR reporting in most clinical laboratory guidelines, offering better accuracy across a wider range of kidney function levels, particularly in patients with higher GFR values.
Serum creatinine alone is an imperfect kidney function marker because its concentration is influenced by muscle mass, age, sex, and diet in ways that make it a poor early indicator of declining function. A patient with large muscle mass may have serum creatinine well within the laboratory’s reference interval even as their GFR has fallen significantly below normal. Cystatin C, a small protein produced at a constant rate by all nucleated cells and freely filtered by the glomerulus, offers a muscle-independent alternative that improves detection of early kidney function decline. Combined creatinine-cystatin C equations provide better risk stratification than either marker alone, particularly in patients whose creatinine-based eGFR may misrepresent their true functional reserve.
Urine albumin-to-creatinine ratio (uACR) adds the dimension of glomerular permeability to kidney assessment. Persistent albuminuria above 30 mg/g indicates kidney damage even when eGFR is still normal or mildly reduced, and uACR combined with eGFR is the basis for the CKD staging system that guides clinical management decisions from blood pressure targets to medication choices to timing of nephrology referral.
Electrolyte measurements, including sodium, potassium, chloride, bicarbonate, calcium, phosphate, and magnesium, monitor the consequences of kidney dysfunction on fluid and acid-base homeostasis. Critically elevated or depressed potassium values trigger some of the most urgent critical value notifications in clinical laboratory practice, because severe hyperkalemia and hypokalemia both pose immediate risks of fatal cardiac arrhythmia.
Tumor Markers: Promise, Limitations, and Appropriate Use
Clinical chemistry’s contribution to oncology centers on serum tumor markers, soluble proteins, glycoproteins, and other molecules elevated in certain malignancies, whose measurement in serum provides a biochemical window into tumor biology. The appropriate use of tumor markers requires understanding what they can and cannot do diagnostically, and this nuance is one of clinical chemistry’s most important interpretive contributions.
Alpha-fetoprotein (AFP), originally an embryonic protein, is elevated in a significant proportion of hepatocellular carcinomas and non-seminomatous germ cell tumors of the testis and ovary. Carcinoembryonic antigen (CEA) is widely used for monitoring colorectal cancer recurrence after resection, with rising CEA values prompting imaging investigations even before clinical symptoms develop. CA-125 is the standard biomarker for monitoring treatment response and detecting recurrence in ovarian cancer, with levels drawn every three months for two years after definitive treatment according to established guidelines. Prostate-specific antigen (PSA) is the sole tumor marker with sufficient sensitivity for population-level screening in a defined cancer type, though its use in prostate cancer screening continues to involve clinical judgment about the tradeoff between detection and overdiagnosis.
The critical qualification that applies to most serum tumor markers is that, except PSA in the appropriate context, they lack sufficient sensitivity and specificity to function as standalone screening tests for cancer in asymptomatic populations. CEA can be elevated in inflammatory bowel disease, smoking, and non-colorectal malignancies. CA-125 is elevated in endometriosis, pelvic inflammatory disease, and other non-malignant conditions. AFP rises during pregnancy and in benign liver conditions. These limitations mean that tumor markers are most valuable in contexts where the pre-test probability of malignancy is already elevated, where a clinical diagnosis needs biochemical confirmation, or where an established diagnosis requires biochemical monitoring over time.
The emerging field of liquid biopsy, which uses clinical chemistry methods to detect circulating tumor DNA, circulating tumor cells, and exosomal markers in blood, is extending the diagnostic reach of clinical chemistry further into oncology. Early detection of tumor-derived mutations in plasma, longitudinal monitoring of treatment response through circulating tumor DNA kinetics, and identification of acquired resistance mutations without repeat tissue biopsy represent genuine advances in applying biochemical measurement to cancer management.
The Expanding Horizon of Clinical Chemistry
The global clinical chemistry analyzer market is projected by Renub Research to grow from $14.74 billion in 2024 to $21.61 billion by 2033, expanding at a CAGR of 4.35 percent. This trajectory reflects not only rising diagnostic demand from an aging, chronically ill global population but also the entry of new biomarker classes into routine clinical use. Glial fibrillary acidic protein (GFAP) in blood is emerging as a clinical chemistry biomarker for neurological injury and, potentially, Alzheimer’s disease detection. High-sensitivity assays for inflammatory markers including C-reactive protein and interleukin-6 are finding roles in cardiovascular risk stratification beyond their traditional use in infection monitoring. Metabolomics, the comprehensive measurement of small molecules in biological fluids, is moving from research tools toward clinical application in inherited metabolic disorders and precision oncology.
Through all of these advances, the fundamental principle that defines the role of clinical chemistry in disease diagnosis remains unchanged: reliable measurement of chemical constituents in human specimens, governed by rigorous quality standards, produces the objective biochemical evidence that clinicians need to make diagnostic decisions they can defend and that patients can trust.
Conclusion
Clinical chemistry is the discipline that converts the chemistry of the human body into the language of clinical decision-making. From the hemoglobin A1c that diagnoses diabetes to the troponin that confirms myocardial infarction, from the ALT pattern that distinguishes alcoholic from viral liver disease to the eGFR that stages chronic kidney disease, and from the CEA that signals colorectal cancer recurrence to the emerging blood biomarkers of neurological injury, clinical chemistry provides the biochemical foundation on which modern diagnosis is built.
As chronic disease burden grows, as precision medicine demands more specific biochemical characterization of individual patients, and as point-of-care testing extends clinical chemistry into settings far beyond the central laboratory, the discipline’s contribution to disease diagnosis will only expand. Understanding what clinical chemistry measures, how to interpret what it finds, and what its limitations require of the clinicians who use it is knowledge that belongs not just to laboratory professionals but to the entire clinical team that patient care demands.
Bio-Reach is a non-profit organization dedicated to advancing Laboratory Medicine through advocacy, education, and global collaboration. To learn more or get involved, visit bio-reach.org.
